| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 05/16/2024 | 4:05PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 04/02/2024 | 7:00AM | GlobeNewswire Inc. | Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million | NASDAQ:ROIV | Roivant Sciences Ltd |
| 03/26/2024 | 6:22PM | PR Newswire (US) | Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 02/13/2024 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 01/30/2024 | 4:05PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 12/20/2023 | 4:30PM | GlobeNewswire Inc. | Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
| 12/14/2023 | 9:00AM | GlobeNewswire Inc. | Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
| 11/28/2023 | 7:00AM | GlobeNewswire Inc. | Roivant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential | NASDAQ:ROIV | Roivant Sciences Ltd |
| 11/27/2023 | 8:00AM | GlobeNewswire Inc. | Roivant and Priovant Announce Results from Phase 2 Study of Oral Brepocitinib in Systemic Lupus Erythematosus | NASDAQ:ROIV | Roivant Sciences Ltd |
| 11/13/2023 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 11/10/2023 | 8:00AM | GlobeNewswire Inc. | Roivant Announces Appointment of Mayukh Sukhatme to Its Board of Directors | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/30/2023 | 5:30PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Second Quarter Ended September 30, 2023, and Provide Business Update on Monday, November 13, 2023 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/23/2023 | 3:41PM | Dow Jones News | Trending: Roche to Buy Telavant From Roivant and Pfizer | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/23/2023 | 7:18AM | IH Market News | Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/23/2023 | 4:16AM | Dow Jones News | Roche to Buy Telavant From Roivant, Pfizer in Deal Worth Up to $7.25 Billion -- Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/23/2023 | 1:50AM | Dow Jones News | Roche to Buy Telavant From Roivant Sciences and Pfizer in $7.25 Billion Deal | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/23/2023 | 1:00AM | GlobeNewswire Inc. | Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | NASDAQ:ROIV | Roivant Sciences Ltd |
| 10/13/2023 | 8:00AM | GlobeNewswire Inc. | Covant Therapeutics Appoints Vincent Hennemand as Chief Executive Officer | NASDAQ:ROIV | Roivant Sciences Ltd |
| 09/26/2023 | 6:00AM | GlobeNewswire Inc. | Roivant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results | NASDAQ:ROIV | Roivant Sciences Ltd |
| 09/11/2023 | 8:00AM | GlobeNewswire Inc. | Roivant Announces Completion of Redemption of its Outstanding Warrants | NASDAQ:ROIV | Roivant Sciences Ltd |
| 08/17/2023 | 4:05PM | GlobeNewswire Inc. | Roivant Announces Redemption Fair Market Value in Connection with Redemption of its Outstanding Warrants | NASDAQ:ROIV | Roivant Sciences Ltd |
| 08/14/2023 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 08/03/2023 | 4:05PM | GlobeNewswire Inc. | Roivant to Report Financial Results for the Quarter Ended June 30, 2023, and Provide Business Update on Monday, August 14, 2023 | NASDAQ:ROIV | Roivant Sciences Ltd |
| 08/02/2023 | 4:05PM | GlobeNewswire Inc. | Roivant Announces Redemption of Outstanding Warrants | NASDAQ:ROIV | Roivant Sciences Ltd |
| 07/27/2023 | 8:00AM | GlobeNewswire Inc. | Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease | NASDAQ:ROIV | Roivant Sciences Ltd |
| 07/14/2023 | 7:51AM | IH Market News | Friday’s Wall Street Highlights: JPMorgan Chase, Coinbase, UPS, Theseus Pharmaceuticals, and more | NASDAQ:ROIV | Roivant Sciences Ltd |
| 07/11/2023 | 8:00AM | GlobeNewswire Inc. | Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovators Program | NASDAQ:ROIV | Roivant Sciences Ltd |
| 06/28/2023 | 8:57AM | GlobeNewswire Inc. | UPDATE -- Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |
| 06/28/2023 | 7:00AM | GlobeNewswire Inc. | Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update | NASDAQ:ROIV | Roivant Sciences Ltd |